

Learn about Gloperba side effects, from common GI symptoms to serious warning signs. Know what to expect and when to seek medical attention.
Gloperba (Colchicine oral solution, 0.6 mg/5 mL) is the only FDA-approved liquid form of Colchicine, used for the prophylaxis of gout flares in adults. Like all medications, it comes with potential side effects. The good news is that most people tolerate Gloperba well when taken as prescribed — but it's important to know what to watch for.
In this guide, we'll break down the common and serious side effects of Gloperba, what's normal versus what needs medical attention, and practical tips for managing side effects so you can stay on track with your gout prevention plan.
Gloperba contains Colchicine, which works by inhibiting tubulin polymerization — essentially disrupting the microtubules that cells need to function. This reduces the migration of neutrophils (white blood cells) to inflamed joints and decreases inflammatory mediators that cause gout flares.
The same mechanism that makes Colchicine effective against gout can also affect rapidly dividing cells elsewhere in your body, particularly in the gastrointestinal tract. That's why GI side effects are the most common complaint.
These side effects are relatively frequent and usually manageable. They often improve as your body adjusts to the medication:
Diarrhea is the most commonly reported side effect of Colchicine products, including Gloperba. It occurs because Colchicine affects the rapidly dividing cells lining your intestines.
Some patients experience nausea, especially when first starting Gloperba or after a dose increase.
Cramping or discomfort in the stomach area can occur alongside diarrhea and nausea.
Some patients report a sore throat or discomfort in the throat area while taking Gloperba.
While rare, Gloperba can cause serious side effects that require immediate medical attention. Do not ignore these warning signs:
Colchicine can affect your bone marrow's ability to produce blood cells. Watch for:
Action: Call your doctor immediately. You may need blood tests to check your cell counts.
Colchicine can cause muscle breakdown, especially when combined with certain other medications like statins. Symptoms include:
Action: Stop taking Gloperba and seek medical attention immediately. Rhabdomyolysis can lead to kidney damage if not treated promptly.
In some cases, Colchicine can cause nerve and muscle damage, particularly with long-term use or in patients with kidney or liver problems. Signs include:
Action: Contact your doctor right away. Dose adjustment or discontinuation may be necessary.
Colchicine overdose can be fatal. Seek emergency medical help if you experience:
Action: Call 911 or go to the nearest emergency room immediately.
Certain conditions and medications can raise your risk of experiencing serious side effects from Gloperba:
The side effect profile of Gloperba is essentially the same as other Colchicine products like Colcrys, Mitigare, and generic Colchicine tablets. The active ingredient is identical — it's just delivered in a liquid form instead of a tablet or capsule.
Some patients actually report fewer GI side effects with the liquid form because it allows for more precise dosing and may be absorbed more evenly. However, this varies from person to person.
Contact your doctor if you experience:
Your doctor may adjust your dose, change your dosing schedule, or in some cases recommend an alternative medication.
If you're currently taking Gloperba and need help finding it in stock, MedFinder can help you locate pharmacies near you that carry it.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.